> The company says that the drug was generally well tolerated, but that’s on the oncology scale.

> ...

> He’s been on daraxonrasib since early this year, and describes it this way: “. . .it’s a nasty drug. It causes crazy stuff like my body can’t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn’t be bleeding” If you go to that link above, be prepared, because he also looks like he’s had aqua regia thrown all over him (and apparently feels a bit like that, too). But his tumor volume has gone down by about 75%, and there’s a very strong chance that he wouldn’t still be alive at all without having gone on the drug.

That’s like talking about the ROI of a winning lottery ticket.

We can’t know ahead of time which medicine works so you need to fund many teams at the beginning.

While not fully approved, the company has early access available to people who meet the treatment criteria and would potentially benefit. Their HCP should evaluate this (it's not all types of pancreatic cancer, and it's not a silver bullet - but it looks like its double the survival time than current chemo). Hopefully this evolves into a new class of treatment.

Always baffling to me that people accuse researchers and doctors, people who have devoted their life to helping others, of brazen greed and deception. With no evidence, of course. Maybe the accusation says more about you than about them?